Literature DB >> 200162

Primary type V hyperlipoproteinemia. A descriptive study in 32 families.

B H Greenberg, W C Blackwelder, R I Levy.   

Abstract

We have studied 32 kindreds identified by propositi with primary type V hyperlipoproteinemia. The clinical presentation, metabolic associations, and natural history confirm the distinctiveness of primary type V hyperlipoproteinemia from other lipoprotein abnormalities. Although the underlying defect(s) remains unknown, several factors such as obesity, alcohol, drugs, and diet are able to modify the glyceridemia, the major manifestation of this disorder. Abnormalities of postheparin lipolytic activity or its subfractions do not appear to be involved in the pathogenesis of primary type V. The prevalence of hyperuricemia, diabetes, pancreatitis, and xanthomatosis appears high among the 32 propositi; the last two entities are much less prevalent in the relatives, even among those relatives classified as hyperglyceridemic. There is no evidence in these families of excessive coronary artery disease prevalence. Triglyceride levels are positively associated with age in this population, especially among women. Average triglyceride levels were lower for women than for men before age 50.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 200162     DOI: 10.7326/0003-4819-87-5-526

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  6 in total

1.  Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation.

Authors:  D E Wilson; M Emi; P H Iverius; A Hata; L L Wu; E Hillas; R R Williams; J M Lalouel
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

2.  The natural history and surgical significance of hyperlipemic abdominal crisis.

Authors:  A Miller; R S Lees; M A McCluskey; A L Warshaw
Journal:  Ann Surg       Date:  1979-09       Impact factor: 12.969

3.  Type V hyperlipoproteinaemia in neonates.

Authors:  G N Thompson; A J Knight; I H Craig; J L Bresson
Journal:  Arch Dis Child       Date:  1987-09       Impact factor: 3.791

4.  Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia.

Authors:  G Ghiselli; E J Schaefer; L A Zech; R E Gregg; H B Brewer
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

5.  Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy.

Authors:  Charles J Glueck; Naseer Khan; Muhammad Riaz; Jagjit Padda; Zia Khan; Ping Wang
Journal:  Lipids Health Dis       Date:  2012-10-30       Impact factor: 3.876

Review 6.  Current Diagnosis and Management of Primary Chylomicronemia.

Authors:  Hiroaki Okazaki; Takanari Gotoda; Masatsune Ogura; Shun Ishibashi; Kyoko Inagaki; Hiroyuki Daida; Toshio Hayashi; Mika Hori; Daisaku Masuda; Kota Matsuki; Shinji Yokoyama; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-13       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.